According to Robbie McCarthy, VP Immunology, Rare Disease & Patient Portfolio at Spherix Global Insights, “Patient education on biologic treatment choices becomes increasingly important when the patient base, such as we are seeing in PsA, actively participates in treatment decisions.”
Surveyed rheumatologists in the study also reveal that one-quarter of their PsA patients treated with biologics or Otezla will switch brands in a given year. Outside of patient influence, the most common drivers behind the decision to switch from a specific biologic/Otezla treatment involve arthritis and skin related efficacy issues. Further biologic and Otezla switching dynamics are covered in depth in RealWorld Dynamix™: Biologic & Otezla Switching in Psoriatic Arthritis, which includes data from 200 surveyed U.S. rheumatologists and analysis of nearly 1000 de-identified psoriatic arthritis (PsA) patient records.
About Spherix Global Insights
Spherix Global Insights is a newly established business intelligence and market research company. We specialize in renal, autoimmune, neurologic and rare disease markets. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.
For more information contact:
Dan Cassidy, Business Development